Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
20.86
-0.15 (-0.71%)
At close: May 22, 2026, 4:00 PM EDT
20.56
-0.30 (-1.42%)
After-hours: May 22, 2026, 7:52 PM EDT
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Arcutis Biotherapeutics stock have a consensus rating of "Buy" and an average price target of $34.63, which forecasts a 66.01% increase in the stock price over the next year. The lowest target is $33 and the highest is $36.
Price Target: $34.63 (+66.01%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +72.58% | May 7, 2026 |
| Mizuho | Mizuho | Buy Maintains $37 → $35 | Buy | Maintains | $37 → $35 | +67.79% | Mar 2, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $34 → $35 | Strong Buy | Maintains | $34 → $35 | +67.79% | Feb 27, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $30 → $35 | Strong Buy | Maintains | $30 → $35 | +67.79% | Feb 26, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $34 | Strong Buy | Maintains | $30 → $34 | +62.99% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
507.11M
from 376.07M
Increased by 34.84%
Revenue Next Year
658.08M
from 507.11M
Increased by 29.77%
EPS This Year
0.11
from -0.13
EPS Next Year
1.05
from 0.11
Increased by 837.90%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 526.4M | 737.2M | ||||||
| Avg | 507.1M | 658.1M | ||||||
| Low | 480.8M | 605.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 40.0% | 45.4% | ||||||
| Avg | 34.8% | 29.8% | ||||||
| Low | 27.8% | 19.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.35 | 1.69 | ||||||
| Avg | 0.11 | 1.05 | ||||||
| Low | -0.05 | 0.45 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 1,413.6% | ||||||
| Avg | - | 837.9% | ||||||
| Low | - | 303.6% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.